Silver Book Fact
According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become dependent on the growth signals that are mediated through the epidermal growth factor receptor, blocking it may stop the growth of cancer cells and eradicate existing cancer cells.
Selected Medicines in Development for Cancer. http://www.innovation.org/index.cfm/FutureOfInnovation/NewMedicinesinDevelopment/Selected%20Medicines%20in%20Development%20for%20Cancer